Biodesix launches $35M prospectus
BOULDER — Biodesix Inc. (Nasdaq: BDSX) launched a $35 million prospectus last week, offering more than 30 million shares of its common stock at a price of $1.15 per share.
Biodesix is a life sciences company focused on developing new lung disease diagnostic technologies.
According to the prospectus, Biodesix “currently expects to use the net proceeds from this offering for commercial expansion of sales, supporting our product pipeline, research and development and for general corporate purposes.”
SPONSORED CONTENT
BOULDER — Biodesix Inc. (Nasdaq: BDSX) launched a $35 million prospectus last week, offering more than 30 million shares of its common stock at a price of $1.15 per share.
Biodesix is a life sciences company focused on developing new lung disease diagnostic technologies.
According to the prospectus, Biodesix “currently expects to use the net proceeds from this offering for commercial expansion of sales, supporting our product pipeline, research and development and for general corporate purposes.”
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…